Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio sobre la tolerabilidad, seguridad y eficacia de Asciminib en pacientes con leucemia mieloide crónica en fase crónica con cromosoma Filadelfia positivo en Alemania (ASC2ADHERE)

5 de noviembre de 2026 actualizado por: Novartis Pharmaceuticals

Estudio no intervencionista sobre la tolerabilidad, seguridad y eficacia de asciminib en pacientes recién diagnosticados y pretratados con leucemia mieloide crónica con cromosoma Filadelfia positivo en fase crónica en Alemania - el estudio ASC2ADHERE

The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI).

Descripción general del estudio

Estado

Reclutamiento

Tipo de estudio

De observación

Inscripción (Estimado)

380

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: Novartis Pharmaceuticals

Ubicaciones de estudio

      • Amberg, Alemania, 92224
        • Reclutamiento
        • Novartis Investigative Site
      • Bad Friedrichshall, Alemania, 74177
        • Reclutamiento
        • Novartis Investigative Site
      • Bad Liebenwerda, Alemania, 04924
        • Reclutamiento
        • Novartis Investigative Site
      • Bad Saarow, Alemania, 15526
        • Reclutamiento
        • Novartis Investigative Site
      • Berlin, Alemania, 10437
        • Reclutamiento
        • Novartis Investigative Site
      • Berlin, Alemania, 10365
        • Reclutamiento
        • Novartis Investigative Site
      • Berlin, Alemania, 12552
        • Reclutamiento
        • Novartis Investigative Site
      • Berlin, Alemania, 10559
        • Reclutamiento
        • Novartis Investigative Site
      • Berlin, Alemania, 12487
        • Reclutamiento
        • Novartis Investigative Site
      • Bremerhaven, Alemania, 27568
        • Reclutamiento
        • Novartis Investigative Site
      • Buchholz Nordheide, Alemania, 21244
        • Reclutamiento
        • Novartis Investigative Site
      • Cottbus, Alemania, 03046
        • Reclutamiento
        • Novartis Investigative Site
      • Deggendorf, Alemania, 94469
        • Reclutamiento
        • Novartis Investigative Site
      • Detmold, Alemania, 32756
        • Reclutamiento
        • Novartis Investigative Site
      • Dorfen, Alemania, 84405
        • Reclutamiento
        • Novartis Investigative Site
      • Dortmund, Alemania, 44263
        • Reclutamiento
        • Novartis Investigative Site
      • Dresden, Alemania, 01307
        • Reclutamiento
        • Novartis Investigative Site
      • Dresden, Alemania, 01127
        • Reclutamiento
        • Novartis Investigative Site
      • Düren, Alemania, 52353
        • Reclutamiento
        • Novartis Investigative Site
      • Erfurt, Alemania, 99085
        • Reclutamiento
        • Novartis Investigative Site
      • Erfurt, Alemania, 99084
        • Reclutamiento
        • Novartis Investigative Site
      • Eschweiler, Alemania, 52249
        • Reclutamiento
        • Novartis Investigative Site
      • Göttingen, Alemania, 37073
        • Reclutamiento
        • Novartis Investigative Site
      • Hanover, Alemania, 30161
        • Reclutamiento
        • Novartis Investigative Site
      • Hanover, Alemania, 30625
        • Reclutamiento
        • Novartis Investigative Site
      • Hildesheim, Alemania, 31135
        • Reclutamiento
        • Novartis Investigative Site
      • Kiel, Alemania, 24105
        • Reclutamiento
        • Novartis Investigative Site
      • Leipzig, Alemania, 04103
        • Reclutamiento
        • Novartis Investigative Site
      • Leverkusen, Alemania, 51375
        • Reclutamiento
        • Novartis Investigative Site
      • Mutlangen, Alemania, 73557
        • Reclutamiento
        • Novartis Investigative Site
      • Naunhof, Alemania, 04683
        • Reclutamiento
        • Novartis Investigative Site
      • Neuss, Alemania, 41462
        • Reclutamiento
        • Novartis Investigative Site
      • Offenburg, Alemania, 77654
        • Reclutamiento
        • Novartis Investigative Site
      • Oldenburg, Alemania, 26121
        • Reclutamiento
        • Novartis Investigative Site
      • Parchim, Alemania, 19370
        • Reclutamiento
        • Novartis Investigative Site
      • Potsdam, Alemania, 14467
        • Reclutamiento
        • Novartis Investigative Site
      • Potsdam, Alemania, 14482
        • Reclutamiento
        • Novartis Investigative Site
      • Schorndorf, Alemania, 73614
        • Reclutamiento
        • Novartis Investigative Site
      • Schwetzingen, Alemania, 68723
        • Reclutamiento
        • Novartis Investigative Site
      • Soest, Alemania, 59494
        • Reclutamiento
        • Novartis Investigative Site
      • Stade, Alemania, 21680
        • Reclutamiento
        • Novartis Investigative Site
      • Torgau, Alemania, 04860
        • Reclutamiento
        • Novartis Investigative Site
      • Ulm, Alemania, 89081
        • Reclutamiento
        • Novartis Investigative Site
      • Wetzlar, Alemania, 35578
        • Reclutamiento
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Baden-Baden, Baden-Wurttemberg, Alemania, 76532
        • Reclutamiento
        • Novartis Investigative Site
      • Heidenheim, Baden-Wurttemberg, Alemania, 89522
        • Reclutamiento
        • Novartis Investigative Site
      • Schwäbisch Hall, Baden-Wurttemberg, Alemania, 74523
        • Reclutamiento
        • Novartis Investigative Site
      • Winnenden, Baden-Wurttemberg, Alemania, 71364
        • Reclutamiento
        • Novartis Investigative Site
    • Bavaria
      • Aschaffenburg, Bavaria, Alemania, 63739
        • Reclutamiento
        • Novartis Investigative Site
      • Augsburg, Bavaria, Alemania, 86152
        • Reclutamiento
        • Novartis Investigative Site
      • Donauwörth, Bavaria, Alemania, 86609
        • Reclutamiento
        • Novartis Investigative Site
      • Herrsching am Ammersee, Bavaria, Alemania, 82211
        • Reclutamiento
        • Novartis Investigative Site
      • Kempten (Allgäu), Bavaria, Alemania, 87439
        • Reclutamiento
        • Novartis Investigative Site
      • Landsberg am Lech, Bavaria, Alemania, 86899
        • Reclutamiento
        • Novartis Investigative Site
      • Munich, Bavaria, Alemania, 81241
        • Reclutamiento
        • Novartis Investigative Site
      • Munich, Bavaria, Alemania, 81377
        • Reclutamiento
        • Novartis Investigative Site
      • Regensburg, Bavaria, Alemania, 93053
        • Reclutamiento
        • Novartis Investigative Site
    • Free Hanseatic City of Bremen
      • Bremerhaven, Free Hanseatic City of Bremen, Alemania, 27576
        • Reclutamiento
        • Novartis Investigative Site
    • Hesse
      • Kassel, Hesse, Alemania, 34125
        • Reclutamiento
        • Novartis Investigative Site
      • Offenbach, Hesse, Alemania, 63065
        • Reclutamiento
        • Novartis Investigative Site
    • Lower Saxony
      • Goslar, Lower Saxony, Alemania, 38642
        • Reclutamiento
        • Novartis Investigative Site
      • Rotenburg (Wümme), Lower Saxony, Alemania, 27356
        • Reclutamiento
        • Novartis Investigative Site
      • Twistringen, Lower Saxony, Alemania, 27239
        • Reclutamiento
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Alemania, 50674
        • Reclutamiento
        • Novartis Investigative Site
      • Cologne, North Rhine-Westphalia, Alemania, 50677
        • Reclutamiento
        • Novartis Investigative Site
      • Cologne, North Rhine-Westphalia, Alemania, 51103
        • Reclutamiento
        • Novartis Investigative Site
      • Solingen, North Rhine-Westphalia, Alemania, 42653
        • Reclutamiento
        • Novartis Investigative Site
      • Wesel, North Rhine-Westphalia, Alemania, 46483
        • Reclutamiento
        • Novartis Investigative Site
    • Saxony
      • Zittau, Saxony, Alemania, 02763
        • Reclutamiento
        • Novartis Investigative Site
    • Saxony-Anhalt
      • Halle, Saxony-Anhalt, Alemania, 06110
        • Reclutamiento
        • Novartis Investigative Site
      • Merseburg, Saxony-Anhalt, Alemania, 06217
        • Reclutamiento
        • Novartis Investigative Site
    • Schleswig-Holstein
      • Oldenburg in Holstein, Schleswig-Holstein, Alemania, 23758
        • Reclutamiento
        • Novartis Investigative Site
    • Thuringia
      • Altenburg, Thuringia, Alemania, 04600
        • Reclutamiento
        • Novartis Investigative Site
      • Saalfeld, Thuringia, Alemania, 07318
        • Reclutamiento
        • Novartis Investigative Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 100 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Adult Ph+ CML-CP patients, either newly diagnosed or previously treated with one ATP-competitive TKI, who initiate TKI treatment as recommended by the treating physician in a hematology center in Germany.

Descripción

Inclusion criteria:

  1. Written informed consent must be obtained before participation in the study/prior to any study-related documentation.
  2. Adult patients (≥18 years of age) with a confirmed diagnosis of Ph+ CML-CP. The presence of the Philadelphia chromosome may alternatively be confirmed by molecular detection of a BCR::ABL1 fusion gene/transcript (e.g., by reverse transcription polymerase chain reaction (RT-PCR)), in accordance with the World Health Organization (WHO) 2022 classification.
  3. Patients who are either newly diagnosed or have received treatment with exactly one prior TKI. Prior TKI treatment is only permitted for patients in the Asciminib Cohort. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be newly diagnosed and must not have received any prior TKI treatment.
  4. Patients for whom the treating physician has made a clinical decision to initiate treatment with asciminib or another TKI (imatinib, dasatinib, bosutinib, nilotinib) as part of routine care. The clinical decision for treatment must have been made prior to enrollment. Treatment must not have started more than 14 days before study inclusion, and treatment may also begin after baseline assessment.
  5. Patients willing to participate in routine follow-up visits and complete patient-reported outcome questionnaires over the course of the study.

Exclusion criteria:

  1. Patients with contraindications to their respective chronic myeloid leukemia (CML) treatment as per the applicable Summary of Product Characteristics (SmPC) and relevant national treatment guidelines (e.g. Onkopedia CML), as well as additional disease- or treatment-related characteristics associated with distinct clinical scenarios that differ from the intended study population, including situations with specific treatment requirements or limited comparability, in which reliable interpretation of study outcomes may not be feasible, including the following asciminib specific considerations:

    • In first- or second-line treatment: presence of BCR::ABL1 fusion transcripts lacking exon a2 (e.g. e13a3, e14a3, e1a3).

    • In second-line treatment:

      • known BCR::ABL1 mutations associated with partial or complete resistance to asciminib (e.g. M244V, F359I/V/C).
      • presence of the BCR::ABL1 T315I mutation, regardless of eligibility for treatment according to SmPC (e.g., specific indication and dosing regimens).
  2. Patients receiving or planned to receive asciminib or other TKIs outside the approved label (off-label use), including use in unapproved dosing regimens or frequency not covered by the respective SmPC.

  3. Patients currently participating in an interventional clinical trial.

  4. Patients unable or unwilling to provide written informed consent.

  5. Patients who are unable to reliably complete patient-reported outcome questionnaires due to cognitive or language limitations relevant to the study assessments.

  6. Patients for whom long-term follow-up is not feasible due to expected relocation or other logistical constraints.

  7. The restriction to a maximum of one prior ATP-competitive TKI applies exclusively to patients treated with asciminib. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be TKI-naïve and are included at the start of their first-line TKI therapy and are not eligible if they have received any prior TKI treatment.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Asciminib Cohort

Adult patients with Ph+ CML-CP, either newly diagnosed or previously treated with one TKI, who are treated with asciminib.

Imatinib Cohort

Adult patients newly diagnosed with Ph+ CML-CP treated with imatinib who have not received any prior TKI treatment.

Second-generation TKI Cohort

Adult patients newly diagnosed with Ph+ CML-CP treated with dasatinib, bosutinib, or nilotinib who have not received any prior TKI treatment.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Patients With Major Molecular Response (MMR) at 12 Months
Periodo de tiempo: Month 12

MMR is defined as a BCR::ABL1 level ≤ 0.1% according to the International Scale (IS).

Month 12

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Patients by Reason for TKI Treatment Decision Documented by the Treating Physician
Periodo de tiempo: Valor inicial
Valor inicial
Porcentaje de pacientes con reducción de dosis por motivo de reducción de dosis
Periodo de tiempo: 3, 6, 9, 12, 15, 18, 21 y 24 meses
3, 6, 9, 12, 15, 18, 21 y 24 meses
Porcentaje de pacientes con interrupción del tratamiento por motivo de interrupción
Periodo de tiempo: 3, 6, 9, 12, 15, 18, 21 y 24 meses
3, 6, 9, 12, 15, 18, 21 y 24 meses
Porcentaje de pacientes que interrumpieron el tratamiento por motivo de interrupción
Periodo de tiempo: 3, 6, 9, 12, 15, 18, 21 y 24 meses
3, 6, 9, 12, 15, 18, 21 y 24 meses
Tiempo hasta la discontinuación del tratamiento
Periodo de tiempo: 3, 6, 9, 12, 15, 18, 21 y 24 meses
3, 6, 9, 12, 15, 18, 21 y 24 meses
Tiempo hasta la Interrupción del Tratamiento
Periodo de tiempo: 3, 6, 9, 12, 15, 18, 21 y 24 meses
3, 6, 9, 12, 15, 18, 21 y 24 meses
Tiempo hasta la Reducción de la Dosis
Periodo de tiempo: 3, 6, 9, 12, 15, 18, 21 y 24 meses
3, 6, 9, 12, 15, 18, 21 y 24 meses
Tiempo hasta la Interrupción del Tratamiento debido a Eventos Adversos (TTDAE)
Periodo de tiempo: 3, 6, 9, 12, 15, 18, 21 y 24 meses
3, 6, 9, 12, 15, 18, 21 y 24 meses
Percentage of Patients by Clinical Characteristic
Periodo de tiempo: Baseline

Characteristics include, but are not limited to, detection of Philadelphia chromosome or BCR::ABL1 transcript, prior treatment, and Eastern Cooperative Oncology Group (ECOG) performance status.

Baseline
Percentage of Patients With Early Molecular Response (EMR) at 3 Months
Periodo de tiempo: Month 3

EMR is defined as BCR::ABL1 ≤10% IS.

Month 3
Percentage of Patients With Molecular Response 2 (MR2)
Periodo de tiempo: 3, 6, 9, 12, 15, 18, 21, and 24 months

MR2 is defined as BCR::ABL1 ≤1% IS.

3, 6, 9, 12, 15, 18, 21, and 24 months
Percentage of Patients With MMR
Periodo de tiempo: 3, 6, 9, 15, 18, 21, and 24 months

MMR is defined as BCR::ABL1 ≤0.1% IS.

3, 6, 9, 15, 18, 21, and 24 months
Percentage of Patients With Deep Molecular Response: MR4.0
Periodo de tiempo: 3, 6, 9, 12, 15, 18, 21, and 24 months

Deep Molecular Response (MR4.0): ≤0.01% BCR::ABL1 IS and Reference gene copies >10,000 ABL1 or >24,000 GUSB.

3, 6, 9, 12, 15, 18, 21, and 24 months
Percentage of Patients With Deep Molecular Response: MR4.5
Periodo de tiempo: 3, 6, 9, 12, 15, 18, 21, and 24 months

Deep Molecular Response (MR4.5): ≤0.0032% BCR::ABL1 IS and Reference gene copies >32,000 ABL1 or >77,000 GUSB.

3, 6, 9, 12, 15, 18, 21, and 24 months
Percentage of Patients With Deep Molecular Response: MR5
Periodo de tiempo: 3, 6, 9, 12, 15, 18, 21, and 24 months

Deep Molecular Response (MR5): ≤0.001% BCR::ABL1 IS and Reference gene copies >100,000 ABL1 or >240,000 GUSB.

3, 6, 9, 12, 15, 18, 21, and 24 months
Medication Adherence Report Scale (MARS-5) Score
Periodo de tiempo: 3, 6, 9, 12, 15, 18, 21, and 24 months

The MARS-5 questionnaire is a validated self-report questionnaire developed to assess patient adherence to prescribed medication, focusing on both intentional and unintentional non-adherence. It consists of 5 items, each rated on a 5-point Likert Scale from 0 (always) to 5 (never). The total score ranges from 5 to 25, with higher scores indicating better adherence to treatment.

3, 6, 9, 12, 15, 18, 21, and 24 months
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score
Periodo de tiempo: 3, 6, 9, 12, 15, 18, 21, and 24 months

The EORTC QLQ-C30 contains 30 questions answered by the patient. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role functioning, cognitive, emotional, and social); 3 symptom scales (fatigue, pain, and nausea and vomiting); and a global health status/Quality of Life (QOL) scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but 2 questions have 4-point scales ranging from "Not at all" to "Very much." The 2 questions concerning global health status/QOL have 7-point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, final scores are transformed such that they range from 0-100, where higher scores indicate improvement.

3, 6, 9, 12, 15, 18, 21, and 24 months
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for CML (EORTC QLQ-CML24) Score
Periodo de tiempo: 3, 6, 9, 12, 15, 18, 21, and 24 months

The EORTC QLQ-CML24 was designed to supplement the QLQ-C30 - the QLQ-CML24 is not a stand-alone instrument but is to be used in conjunction with the QLQ-C30.

The EORTC QLQ-CML24 is composed of 4 multi-item scales and 2 single-item scales. The module consists of 24 items assessing symptom burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items are measured on 4 levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores are averaged and transformed to 0 to 100.

A higher score in symptom burden, impact on worry/mood, impact on daily life, and body image problems domains indicates a worse outcome. A higher score in satisfaction with social life and satisfaction with care and information domains indicates a higher level of satisfaction.

3, 6, 9, 12, 15, 18, 21, and 24 months
Work Productivity and Activity Impairment - General Health (WPAI-GH) Score
Periodo de tiempo: 3, 6, 9, 12, 15, 18, 21, and 24 months

The WPAI-GH is a patient-reported 6 item questionnaire which addresses absenteeism, presenteeism, overall work productivity loss, and activity impairment for the 7 days prior to the assessment. Work productivity and activity impairment outcomes are presented as impairment percentages ranging from 0 to 100 with a higher percentage indicating greater impairment and less productivity.

3, 6, 9, 12, 15, 18, 21, and 24 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

17 de abril de 2026

Finalización primaria (Estimado)

30 de septiembre de 2030

Finalización del estudio (Estimado)

30 de septiembre de 2030

Fechas de registro del estudio

Enviado por primera vez

16 de abril de 2026

Primero enviado que cumplió con los criterios de control de calidad

16 de abril de 2026

Publicado por primera vez (Actual)

24 de abril de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

5 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir